Investigating the Link Between Androgen Deprivation Therapy and Dementia

Understanding Prostate Cancer and Androgen Sensitivity

Prostate cancer is characterized by its sensitivity to androgens, which are male sex hormones like testosterone and dihydrotestosterone. One of the primary treatment methods for this cancer is androgen deprivation therapy (ADT), which involves reducing circulating androgens in the body. This can be achieved through various means, including the chronic administration of gonadotropin-releasing hormone (GnRH) agonists, estrogen therapy, or orchiectomy, which is the surgical removal of the testes.

Rising Use of Androgen Deprivation Therapy

The introduction of a blood test for prostate-specific antigen has significantly improved prostate cancer diagnosis. Consequently, the number of diagnosed cases has risen, leading to an increased reliance on androgen deprivation therapy. Approximately half of all men with prostate cancer undergo ADT at some point after diagnosis. This trend indicates that patients are beginning treatment earlier in their disease progression, resulting in longer treatment durations. However, ADT has various side effects, including skeletal fractures, diabetes, obesity, and concerns regarding cognitive functions such as dementia or Alzheimer’s disease.

The Role of Androgens in Cognitive Function

Androgens are thought to influence brain activities because their receptors are located in key areas related to memory and cognitive functions, including the prefrontal cortex and hippocampus. Studies in rodents have shown that testosterone removal can lead to higher production of β-amyloid protein, which is linked to Alzheimer’s disease. In humans, some evidence suggests that men with Alzheimer’s may have lower testosterone levels, but a direct causal relationship between low androgen levels and dementia remains unproven.

Recent Study on ADT and Dementia Risk

A recent study published in JAMA Network Open explored the potential association between androgen deprivation therapy and dementia. Researchers utilized data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results-Medicare-linked database, analyzing information from 154,089 men aged 66 years or older, diagnosed with either local or advanced prostate cancer. Participants were followed for an average of 8.3 years, divided into two groups: those who received ADT within two years of diagnosis and those who did not.

The findings indicated that men undergoing ADT had a higher likelihood of being diagnosed with dementia compared to those who did not receive this therapy (21.6% vs. 15.8%). Similarly, a slight increase in Alzheimer’s disease diagnoses was observed in the ADT group (13.1% vs. 9.4%). Specifically, men receiving ADT were found to be 1.2 times more likely to receive a dementia diagnosis.

Limitations of the Study

As an observational study, this research is subject to confounding biases that can complicate interpretations. The side effects of ADT may contribute to the observed increased dementia risk. Additionally, factors like family history of Alzheimer’s disease, smoking, alcohol consumption, and educational level were not accounted for. Notably, the study did not consider the APOE ε4 gene, which is associated with Alzheimer’s disease and could impact the results. Furthermore, the absence of a matched control group with healthy individuals makes it challenging to contextualize the increased risk of dementia observed in the ADT group. While the study suggests an association between ADT and dementia, it does not establish a direct causative link.

Conclusion

Continued research is essential to fully understand the implications of androgen deprivation therapy on cognitive health in men with prostate cancer.

References

Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nature Reviews Cancer 1, 34 (2001).
Harris, W. P., Mostaghel, E. A., Nelson, P. S. & Montgomery, B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Reviews Urology 6, 76 (2009).
Taylor, L. G., Canfield, S. E. & Du, X. L. Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer. Cancer 115, 2388-2399 (2009).
McHugh, D. J., Root, J. C., Nelson, C. J. & Morris, M. J. Androgen‐deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? Cancer 124, 1326-1334 (2018).
Martins, R. N. & Gandy, S. Prostate cancer: increased dementia risk following androgen deprivation therapy? Nature Reviews Urology 13, 188 (2016).
Nelson, C. J., Lee, J. S., Gamboa, M. C. & Roth, A. J. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 113, 1097-1106 (2008).
Jayadevappa, R. et al. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. JAMA Network Open 2, e196562-e196562 (2019).